Platelet-Derived Growth Factor Receptor Beta Serum Concentrations during First-Line Therapy in Ovarian Cancer

Abstract

Objectives: Angiogenesis plays an important role in ovarian cancer. The interaction of platelet-derived growth factor receptor-beta (PDGFR-β) with vascular endothelial growth factor (VEGF) in the process of angiogenesis may represent an essential feature in the progression of the disease. Methods: Patients with epithelial ovarian cancer, who underwent primary surgery and platinum-based first-line chemotherapy, were included. A total of 133 serum samples from 39 patients were analyzed. Samples were prospectively collected at 4 time points: (1) before surgery, (2) after surgery and before chemotherapy, (3) during chemotherapy and (4) after chemotherapy. Serum PDGFR-β was quantified by ELISA. We analyzed the correlation of serum levels to chemotherapy response, progression-free and overall survival (PFS and OS) and the serum markers CA-125 and VEGF-165. Results: Serum concentration of PDGFR-β ranged between 4 and 72 ng/ml and increased significantly during first-line chemotherapy (p = 0.019). PDGFR-β serum concentrations showed an inverse correlation with CA-125 and VEGF-165 after chemotherapy (r = -0.495, p = 0.003 and r = -0.345, p = 0.04, respectively). Increased PDGFR-β serum levels after chemotherapy were significantly correlated with better PFS (p = 0.026) and OS (p = 0.013) in a univariate analysis. Conclusion: PDGFR-β might be a useful biomarker in terms of prognosis and could be important as antiangiogenic agents become a component of standard treatment in ovarian cancer.

MicroRNA-34A inhibits the growth, invasion and metastasis of gastric cancer by targeting PDGFR and MET expression

“…PDGFR-α overexpression has been observed in metastatic medulloblastoma patient samples, compared with non-metastatic patient samples, and the disruption of PDGFR-α function inhibited the metastatic potential of medulloblastoma cells in vitro [5]. Mathey et al [6] also found that PDGFR-β could be important as an antiangiogenic agent and has since become a component of the standard treatment in ovarian cancer. Furthermore, PDGFR expression levels are associated with the angiogenesis, invasion and metastasis of colon cancer [7–9].…”

Serum detection of blood brain barrier injury in subjects with a history of stroke and transient ischemic attack

“…These covariates were selected because of their role in BBB/pericyte pathophysiology along with CVA development. 13 , 22 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 …”

MicroRNA-499 rs3746444 A/G polymorphism functions as a biomarker to predict recurrence following endoscopic submucosal dissection in primary early gastric cancer

“…The overexpression of PDGFR-α has been observed in metastatic medulloblastoma patient samples, compared with non-metastatic patient samples, in which the disruption of PDGFR-α function inhibited the metastatic potential of medulloblastoma cells in vitro (29). Mathey et al (30) also found that PDGFR-β may be important as an anti-angiogenic agent and has now become a component of the standard treatment of ovarian cancer. Furthermore, the expression levels of PDGFR are associated with the angiogenesis, invasion and metastasis of colon cancer (31)(32)(33).…”